Mohammad Hossein Nazaran

4. Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.

[ 1 ] - Knockdown of HSF1 sensitizes resistant prostate cancer cell line to chemotherapy

The treatment of prostate cancer patients usually starts with androgen ablation and followed by chemotherapy; however, in some cases the tumor develops resistant phenotype. Combination therapy is currently regarded as a cornerstone in cancer therapy to overcome the drug resistance. Herein, we investigated the combinatory effect of Docetaxel and Trastuzumab with a novel nanomedicine, BCc1. Also,...

نویسندگان همکار